Last updated: July 28, 2026
PROGLYCEM (dichloraldiethyl imide) clinical trials update and market forecast (2026)
PROGLYCEM is a legacy antiepileptic brand for congenital hyperinsulinism due to defects in energy regulation. Public clinical-trial activity is limited and mostly historical; there is no current, widely reported late-stage development program driving near-term competitive change. Near-term market exposure is instead driven by supply continuity, off-label neurology use patterns, and payer access for rare-disease pathways, with regulatory risk concentrated in manufacturing and labeling continuity rather than blockbuster-style lifecycle moves.
What clinical trials have been run for PROGLYCEM (dichloraldiethyl imide)?
Featured snippet answer: Clinical evidence for PROGLYCEM is largely older and focused on seizure control in rare refractory epilepsies and metabolic management in congenital hyperinsulinism. Current public reporting of new interventional trials is sparse.
Key historical clinical themes
- Epilepsy endpoints
PROGLYCEM has been used for seizure reduction in patients with refractory epilepsy forms, where ketogenic/energy-modulating strategies were explored before modern precision antiepileptic care.
- Metabolic endpoints tied to congenital hyperinsulinism
The drug’s mechanism supports exploration in disorders involving impaired regulation of glucose metabolism.
What counts as “current” in public reporting
- PROGLYCEM’s trial record is not characterized by ongoing Phase 3 programs.
- New enrollment, protocol amendments, and recruiting activity are not consistently reflected in major trial registries for this product name in the way recent AED lifecycle products are.
Clinical trial bottom line: The product’s evidence base is dominated by earlier studies, and the current landscape is shaped more by access, substitution risk, and manufacturing than by active late-stage clinical development.
Are there active or recruiting clinical trials for PROGLYCEM right now?
Featured snippet answer: Publicly visible recruitment or late-stage development for PROGLYCEM is not prominent; the product behaves like a stable, legacy therapy with limited ongoing interventional trial visibility.
Why active programs matter less for PROGLYCEM than for newer drugs
- PROGLYCEM is not positioned around a large, ongoing registrational trial pipeline.
- Competitive dynamics are more sensitive to supply constraints, generics/authorized supply, and payer reimbursement decisions than to trial-driven indication expansion.
What is the FDA regulatory status of PROGLYCEM (Orange Book status, labeling, approval basis)?
Featured snippet answer: PROGLYCEM is an FDA-approved drug product with an established labeling history. Patent and exclusivity status does not appear to be the primary driver of market access in the same way it is for newer branded therapies.
Regulatory status impact areas
- Labeling continuity: Any changes that narrow use can shift adoption.
- Compounding and substitution behavior: Legacy antiepileptic products sometimes see dosing variability when supply tightens.
- Manufacturing consistency: Rare-product markets are highly sensitive to production interruptions.
How strong is the PROGLYCEM patent estate and what patents protect it?
Featured snippet answer: PROGLYCEM’s IP position is consistent with a legacy product, where core process/formulation protection is typically long expired or near expiration. Market change risk is therefore driven less by new patent listings and more by generic/supply availability.
What generally remains relevant for legacy products
- Process and formulation patents (if any are still listed): can delay certain manufacturing routes or solid dosing changes.
- Method-of-use patents: can affect off-label adoption and payer coverage, but they are usually less central for legacy AEDs than for new mechanism claims.
IP bottom line: For PROGLYCEM, the market is best modeled around supply and access rather than imminent patent challenges.
When does PROGLYCEM lose exclusivity or patent coverage?
Featured snippet answer: For legacy drugs with limited visible development, exclusivity-driven timing is not a dominant public forecasting lever. Market entry and price behavior tend to track historical approvals and manufacturing capacity more than a discrete exclusivity “cliff.”
What generic entry risks exist for PROGLYCEM?
Featured snippet answer: Generic substitution and market share shifts are most sensitive to whether authorized generic supply remains steady and whether any remaining formulation/process constraints affect manufacturability.
Generic entry risk drivers
- Manufacturing capacity: Small-molecule legacy products can face discontinuation risk in low-margin supply.
- Regulatory constraints: If a product’s manufacturing route is difficult to replicate, it can reduce effective generic pressure.
- Payer and specialty channel behavior: Rare-disease prescribing can maintain brand preference even when generics are available.
How does PROGLYCEM compare with newer antiepileptics and energy-metabolism therapies?
Featured snippet answer: PROGLYCEM competes on niche indication fit and tolerability patterns rather than on efficacy breadth. Newer AEDs and metabolic therapies typically dominate mainstream refractory epilepsy strategies.
Competitive positioning
- Niche fit: Used where energy-modulating approaches or specific metabolic seizure drivers align with the clinician’s strategy.
- Switching friction: Established patients can remain on PROGLYCEM due to stability and caregiver familiarity.
- Formulary barriers: Some payers restrict older niche AEDs unless there is documented refractory response.
What is the market size for PROGLYCEM, and how much revenue is at stake?
Featured snippet answer: PROGLYCEM’s market is small and driven by rare pediatric and metabolic/neurology patient populations, plus continuity prescribing.
Market model used for projections
Because PROGLYCEM is not a high-volume blockbuster, market forecast should be treated as a quantity and access model:
- Patient counts within rare epilepsy and metabolic-adjacent use segments
- Retention of current patients (treatment continuation is typically high in stable legacy regimens)
- Supply availability and pharmacy stocking behavior
- Reimbursement and prior authorization friction
Projection implication: Market growth is limited unless PROGLYCEM gains materially broader label recognition or a major payer access policy change occurs.
Market projection (2026–2031): base case, upside, downside
Featured snippet answer: A reasonable forward range treats PROGLYCEM as stable with modest volatility tied to supply continuity and reimbursement pressure, not trial-driven expansion.
Base case (most likely)
- Flat-to-slight decline in net sales, driven by:
- steady generic price pressure where substitution is feasible
- gradual patient movement to newer AED regimens over time
- Stability preserved by:
- high retention in controlled patients
- niche prescriber experience
- continued access for pediatric metabolic seizure management
Upside case
- Net sales stabilization or mild growth if:
- supply remains uninterrupted and specialty channels maintain inventory
- payer coverage improves for legacy metabolic seizure management
- clinicians increase use due to gaps in alternative therapies for specific subpopulations
Downside case
- Net sales decline accelerates if:
- manufacturing disruptions occur
- formulary restrictions tighten
- substitution increases after supply normalization or competitive stocking
Forecast range framing: For legacy niche drugs, the largest swing factor is supply and access, not clinical development.
What manufacturing and supply-chain events could move PROGLYCEM pricing and availability?
Featured snippet answer: For niche legacy brands, supply discontinuations and batch availability drive both short-term shortages and longer-term channel price resets.
Key event types
- Discontinuation or reduced production
- Recalls tied to sterility/quality defects (where applicable to the dosage form)
- Temporary shortages leading to substitution changes
- Reintroduction with altered pricing or contracting terms
What patent litigation or settlements affect PROGLYCEM?
Featured snippet answer: PROGLYCEM’s public litigation footprint is not characterized as a leading driver of near-term market entry risk. Market behavior is more consistent with supply and access dynamics.
How to interpret litigation for legacy products
- If active Paragraph IV cases exist, they would usually be visible through Orange Book-linked filings and court dockets.
- For forecasting, the practical effect is still determined by timing of generic launch and real-world availability, not only by legal outcomes.
What is the competitive landscape for PROGLYCEM in the US?
Featured snippet answer: Competition is dominated by generic substitution where available and by clinical substitution toward newer AED options for refractory epilepsy.
Competitive substitutes
- Newer AEDs with broader evidence and mainstream formulary coverage
- Metabolic and energy-modulating approaches used in specialized centers
Channel dynamics
- Specialty pharmacy distribution and prior authorization can keep legacy brands entrenched longer than pure patent economics would suggest.
Key Takeaways
- PROGLYCEM’s public development profile is legacy-heavy, with limited visible late-stage clinical trial activity driving change.
- Market forecast is primarily an access, supply continuity, and niche retention model.
- Generic and formulary pressure can apply, but patient retention and specialty prescribing patterns tend to dampen rapid share shifts.
- The biggest swing risks are manufacturing continuity, reimbursement restrictions, and inventory/availability disruptions rather than discrete exclusivity cliffs or trial outcomes.
FAQs
- Why does PROGLYCEM remain used in modern epilepsy care despite newer antiepileptics?
- What reimbursement factors most affect access to PROGLYCEM in pediatric neurology?
- How do supply shortages of legacy antiepileptics change substitution behavior in pharmacies?
- What clinical characteristics tend to predict continuation vs switching away from PROGLYCEM?
- How should investors model revenue for niche legacy AEDs when trial pipelines are quiet?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
- ClinicalTrials.gov. US National Library of Medicine.
- FDA drug labeling database (Drugs@FDA). US Food and Drug Administration.
